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Increasing Tumor Antigen Expression Overcomes
“Ignorance” to Solid Tumors via Crosspresentation
by Bone Marrow-Derived Stromal Cells
not account for the consistent rejection of so-called
regressor tumors. When transplanted as solid tumor
fragments, these tumors grow in T cell-deficient animals
but prime CTL responses and are rejected by immuno-
competent hosts (Kripke, 1974; Schreiber, 1999; Ward
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recognize or reject cancer cells expressing lower levels
of antigen only when these cancer cells are embedded
in the stroma of a solid tumor. This stromal “barrier”Summary
was overcome by tumor cells expressing antigens at
levels sufficient for crosspresentation. Thus, the tumorTo explain why solid cancers grow or are rejected, we
examined how the tumor stroma affected the level of stroma may determine if the level of antigen expression
is sufficient to induce an immune response against solidantigen expression necessary to induce an immune
response. We applied a tamoxifen-regulated Cre-loxP tumors.
system to induce a model SIYRYYGL antigen recog-
nized by the 2C T cell receptor. Solid tumors express- Results
ing the antigen at lower levels grew, whereas solid
tumors expressing antigen induced to 26-fold higher 2C TCR Transgenic Mice Reject Solid Tumors
levels were rejected. In contrast, mice rejected cell Expressing Higher but Not Lower Levels
suspensions expressing higher or lower levels of the of the SIY Antigen
antigen. The antigen was likely crosspresented be- The C57BL/6-derived fibrosarcoma MC57 was rejected
cause draining lymph node responses required bone when inoculated as single cells but grew when solid
marrow-derived cells in the tumor stroma. Thus, tumor tumor fragments were used as inoculum (Ochsenbein
antigens expressed at levels sufficient for cross- et al., 1999, 2001, and Table 1). Therefore, this model
presentation by bone marrow-derived stromal cells is appropriate for determining how the tumor stroma
may overcome immunological “ignorance” to solid prevents the rejection of solid tumors. To investigate
tumors. how the stroma prevents tumor rejection, we compared
the differences between MC57 tumors, which were re-
Introduction jected, and MC57 tumors, which grew. To study the
growth or rejection of solid tumors, we used 2C TCR
In solid tumors, malignant cells are enmeshed in a stroma transgenic mice that recognized the SIYRYYGL (SIY)
consisting of a complex network of a microvasculature antigen (Sha et al., 1988; Udaka et al., 1996). 2C T cells
lined by endothelium, bone marrow-derived, and other recognized the synthetic SIY peptide in association with
nonmalignant cells as well as extracellular matrix (Co- the class I molecule Kb. Thus, the SIY antigen can be
tran et al., 1999). Antigenic cancer cells when inoculated either directly presented by MC57 cells expressing SIY
as solid tumor fragments grow in immunocompetent or crosspresented by APCs expressing Kb.
hosts. In contrast, immunocompetent hosts reject sig- We generated an SIY expression construct by fusing
nificantly greater numbers of the same type of cancer three copies of the SIY minigene to the EGFP gene,
cells when these cells are in suspension and devoid of which was used to quantify the level of antigen expres-
stroma (Ochsenbein et al., 1999, 2001; Singh et al., 1992). sion (Figure 1A). The SIY peptides were separated by
Therefore, the stroma may prevent effective immune three amino acid spacers to favor correct processing
responses against these antigenic tumors (Singh et al., of this antigen. We generated MC57 cells containing a
1992). Cancer cells in suspension can localize in the nonretroviral vector pcDNA-SIY to exclude artifacts due
tumor draining lymph nodes (DLN) and directly prime to retroviral infection. This clone, SIY-1 (MFI  1007),
cytotoxic T lymphocytes (CTLs) (Kundig et al., 1995, fluoresced 434-fold more than the neomycin-transfected
1993; Ochsenbein et al., 1999, 2001). Conversely, cancer control (Neo) (MFI  2.32) and was lysed by 2C T cells
cells in a solid tissue may fail to stimulate effective CTL (Figures 1B and 1C). Mice rejected challenges with SIY-1
immunity, presumably because the tumor stroma may solid tumor fragments, whereas mice failed to reject
retain cancer cells from draining to the LN (Ochsenbein MC57 tumors which did not express the SIY gene (Table
et al., 1999, 2001; Speiser et al., 1997; Zinkernagel, 1). The rejection of SIY-1 tumors was not due to the
2000). Thus, the rejection of solid cancers may depend EGFP antigen because C57BL/6-EGFP transgenic mice,
on whether cancer cells directly prime immune re- which are tolerant to EGFP, also rejected SIY-1 tumors.
sponses in the DLN. Since tumor rejection may depend on the level of
However, the absence of cancer cells in the DLN may antigen expression, we created an inducible SIY vector
(iSIY-LEGFP) to generate cell populations that ex-
pressed higher or lower levels of antigen but were de-4 Correspondence: mspiotto@midway.uchicago.edu
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Table 1. Solid Tumors Expressing High Levels of Antigen Are Rejected
Tumor Incidencea in Experiment Number
Cell
Type of Inoculum Line 1b 2c 3d 4d 5d Total
Solid tumor fragments MC57 6/7 4/4 - - - 10/11
SIY-1 0/9 0/6 - - - 0/15j
SIY-2Hi - - - 0/2 0/8h 0/10j
SIY-2Lo - - - 2/2 5/5 7/7
Cell suspension MC57 0/8e - - - - 0/8j
SIY-2Hi - - 0/2f - 0/5i 0/7j
SIY-2Lo - - 0/2f - 0/5i 0/7j
Neo - - 2/2g - 5/5g 7/7
a Tumor incidence was assessed 30 days after tumor challenge.
b MC57 or SIY-1 cell suspensions or tumor fragments were injected into C57BL/6 mice. Results are from three independent experiments.
c MC57 or SIY-1 tumor fragments were injected into C57BL/6-EGFP transgenic mice. Results are from three independent experiments.
d SIY-2Hi, SIY-2Lo, and Neo cell suspensions or tumor fragments were injected into 2C TCR transgenic mice.
eTwo mice were injected with 108, 107, 106, or 105 cells in a single-cell suspension.
f One mouse was injected with 6  106 cells. The remaining mouse was injected with 2  107 cells.
gMice were injected with 6  106 cells.
h One mouse died on d18 but did not have a palpable tumor mass.
i Mice were injected with 2  107 cells.
j p value  0.001
rived from a single clone (Figure 1A). iSIY-LEGFP con- ulated Cre recombinase, MerCreMer (Zhang et al., 1996).
In the presence of tamoxifen, MerCreMer excised thetains a floxed HLA-A2.1-puromycin gene that inhibited
SIY expression. We transfected MC57 cells with iSIY- floxed genes in iSIY-LEGFP to induce higher levels of
SIY expression. For the present study, we used oneLEGFP and pAN-MerCreMer, encoding a tamoxifen reg-
Figure 1. 2C T Cells Equally Lyse MC57 Cells
Expressing Different Levels of the SIY Antigen
(A) Vector design for the pcDNA-SIY and iSIY-
LEGFP.
(B) MC57 cells were transfected with pcDNA-
SIY or iSIY-LEGFP to generate the clones
SIY-1 and SIY-2Lo, respectively. SIY-2Lo
cells were treated with 4-OHTAM for 4 days
to generate SIY-2Hi cells. SIY-1, SIY-2Hi, and
SIY-2Lo express similar levels of Kb but differ-
ent levels of the SIY antigen, as determined by
EGFP fluorescence. For EGFP fluorescence:
shaded curve, SIY transfectant; unshaded
curve, MC57-Neo. For Kb staining: shaded
curve, anti-Kb staining; unshaded curve, sec-
ondary antibody only.
(C) 2C T cells specifically and equally lysed
MC57 cells expressing different levels of the
SIY antigen in a 4.5 hr 51Cr release assay.
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clone, which in the uninduced state (SIY-2Lo) showed with a suspension of 5  106 cancer cells or solid tumor
fragments. After 4 days, analysis of the DLN revealeda 7.8-fold increase of EGFP fluorescence (MFI  18.1)
compared to the Neo clone (Figure 1B). Following that 2C T cells divided similarly in response to chal-
lenges with suspensions of SIY-1, SIY-2Hi, or SIY-2Lo4-hydroxytamoxifen (4-OHTAM) treatment, this clone,
now in the induced state (SIY-2Hi), increased EGFP ex- cells (Figure 2A). In contrast, 2C T cells only proliferated
in response to solid tumors expressing higher levels ofpression by 209-fold (MF1405) and decreased surface
expression of HLA-A2.1 to background levels (data not SIY (Figure 2A). Namely, 2C T cells entered division in
response to SIY-1 or SIY-2Hi tumor fragments (73.1%shown). Since cytometric analysis failed to detect signif-
icant subpopulations expressing high levels of SIY, the and 76.1%, respectively), whereas most of the 2C T cells
(94.9%) did not divide in response to SIY-2Lo tumorlower levels of EGFP fluorescence in SIY-2Lo cells was
not likely due to spontaneous recombination. Rather, fragments.
Since T cell responses depend on the amount of anti-these lower levels were likely due to transcriptional read-
through of the unrecombined gene despite multiple po- gen, we determined whether solid tumors and cell sus-
pensions expressed similar levels of the SIY antigenlyA sites in the floxed HLA-A2.1-puromycin gene. Fur-
thermore, the SIY expression in SIY-2Hi and SIY-2Lo (Figure 2B). As a proxy measure for SIY expression, we
compared lysates of the cancer cell and tumor fragmentcells remained stable for 3–4 weeks in culture or growing
as a solid tumor (data not shown). Increased levels of inocula for EGFP expression by Western analysis (Figure
2B). SIY-1 or SIY-2Hi tumor fragments with a volume ofSIY antigen expression were not likely toxic to the cells
because SIY-2Lo and SIY-2Hi cells grew at similar rates 56  8 mm3 contained 4.1  1.7  106 cancer cells,
similar to the number of cells used as cell suspensionin culture and in C57BL/6-RAG1/ mice (data not
shown). Consistent with previous results in another tu- inoculum (5  106). This value is consistent with the
previously reported range of cancer cells per tumor frag-mor model (Koeppen et al., 1993), 2C T cells similarly
lysed SIY-expressing cancer cells expressing different ment (Ochsenbein et al., 1999; Singh et al., 1992). We
could not detect EGFP expression in SIY-2Lo lysates.levels of antigen (Figure 1C).
We then determined if solid tumors or cell suspen- However, the number of SIY-2Hi cells in an SIY-2Hi tu-
mor fragment should be similar to the number of SIY-sions expressing different levels of antigen grew or were
rejected. In C57BL/6 mice, the SIY antigen was not re- 2Lo cells in an SIY-2Lo tumor fragment because both
cell populations are derived from the same clone. Thesequired for rejection of MC57-SIY cell suspensions be-
cause C57BL/6 mice rejected suspensions of 108 MC57 results indicated that different 2C T cell responses to
SIY-2Lo cell suspensions or tumor fragments were notcancer cells (Ochsenbein et al., 1999, 2001, and Table 1).
SIY-2Lo and SIY-2Hi tumors also expressed MerCreMer likely due to differences in antigen dose. We concluded
that CD8 T cells did respond to suspensions of cancerand HLA-A2.1 antigens, which might affect the growth
or rejection of these tumors in C57BL/6 mice. Therefore, cells expressing lower levels of antigen but failed to
respond to the same cancer cells in the context of awe used 2C TCR transgenic mice which have a limited
T cell repertoire and fail to respond effectively against solid tumor. Therefore, these data suggest that cancer
cells in a solid tissue need to express a relatively highantigens other than SIY as shown by the Neo clone
growing as a cell suspension (Table 1). Three-fold level of antigen in order to stimulate a T cell response.
greater numbers of SIY-2Hi or SIY-2Lo cells in suspen-
sion did not grow in 2C mice, indicating that the rejection Growing Tumors Expressing Higher Levels of Antigen
of MC57 cells depended on the SIY antigen. Solid tumors Induce Greater T Cell Proliferation
expressing higher levels of SIY did not grow, whereas Cancer cells in suspension can form solid tumors that
tumors expressing lower levels of antigen grew. Since grow progressively and escape an immune response.
both tumors were derived from the same clone, our During progressive growth, these cancer cells become
observations were not affected by differences in the encased in stroma. To determine how the level of antigen
growth rates between the SIY-2Hi and SIY-2Lo tumors. expression affected T cell responses to progressively
Thus, in contrast to a cell suspension, the level of antigen growing tumors, we challenged OT-1 mice with SIY-2Lo
expression determined whether a solid tumor grew or or SIY-2Hi cells in suspension since the limited reper-
was rejected. toire of these mice enabled SIY-2Lo and SIY-2Hi cells
to grow out as solid tumors. On day 13, we transferred
CFSE-labeled 2C T cells into the tumor-bearing mice.Suspensions of Cancer Cells Expressing SIY at Higher
or Lower Levels Induce Similar T Cell Responses, At this time, the SIY-Lo tumor had reached a size of 525
mm3 and the SIY-Hi tumor had reached a size of 577.5but Only Solid Tumors that Express Higher
Levels of SIY Induce 2C T Cell Responses mm3. After 3 days, analysis of the DLN revealed that 2C
T cells proliferated considerably more in the drainingin the DLN
To explain why the level of antigen only affected the lymph nodes of mice bearing SIY-2Hi tumors compared
to mice bearing SIY-2Lo tumors (Figure 2D). Our resultsrejection of solid tumors, we compared how 2C T cells
responded to suspensions of cancer cells or solid tu- could not indicate if this limited proliferation was due
to residual traces of antigen from the challenge of themors expressing different levels of antigen. To study T
cell responses, we examined 2C T cell responses in cell suspension or due to the increased antigen load
resulting from the growing tumor. Still, suspensions ofC57BL/6 mice because the high precursor frequency in
2C mice hinders the detection of activated T cells (Pape SIY-2Lo cells that acquired stroma as a growing tumor
(Figure 2D) induced significantly less T cell proliferationet al., 1997). We transferred CFSE-labeled 2C T cells
into C57BL/6 mice which were challenged the next day than the initial challenge of similar cells in suspension
Immunity
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Figure 2. In Contrast to Cell Suspensions,
Only Solid Tumors that Express Higher Levels
of Antigen Induce a T Cell Response in the DLN
(A) C57BL/6 mice were injected with 107
CFSE-labeled 2C T cells and then challenged
with tumor fragments or suspensions of 5 
106 SIY-1, SIY-2Hi, or SIY-2Lo cells. All three
cell lines induced 2C T cell proliferation as a
cell suspension, but T cells only responded
to SIY-1 and SIY-2Hi tumor fragments.
(B) Tumor fragment lysate or cancer cell ly-
sates were analyzed for EGFP expression and
showed comparable levels of the SIY antigen.
For SIY-1 tumors and cell suspensions: Frag,
1:100 dilution of fragment lysate; Cell, 5 
104 cell equivalents. For SIY-2Hi and SIY-2Lo
tumors and cell suspensions: Frag, 1:50 dilu-
tion of fragment lysates; Cell, 1  105 cell
equivalents.
(C) MC57 cells were transfected with igp33-
LEGFP to generate the clone gp33-1Lo.
gp33-1Lo cells were treated with 4-OHTAM
for 4 days to generate gp33-1Hi cells. For
EGFP fluorescence: shaded curve, gp33
transfectant; unshaded curve, MC57-Neo.
(D) OT-1 mice were injected with 5 106 SIY-
2Lo or SIY-2Hi cells in suspension. Thirteen
days after tumor growth, 107 CFSE-labeled
2C T cells were transferred into tumor-bear-
ing mice, and, 3 days later, DLN were ana-
lyzed for T cell proliferation. 2C mice were
injected with 2  106 gp33-1Lo or gp33-1Hi
cells in suspension. Sixteen days after tumor
growth, 107 CFSE-labeled P14 T cells were
transferred into tumor-bearing mice, and, 3
days later, DLN were analyzed for T cell prolif-
eration.
(Figure 2A). Furthermore, the increased tumor mass of Solid Tumors Expressing Higher Levels
of the SIY Antigen Prime Specificthe SIY-2Lo tumors (Figure 2D) did not restore T cell
proliferation to the level attained by challenges of SIY- CTL Responses in C57BL/6 Mice
In studying 2C responses, we used high numbers of2Hi tumor fragments (Figure 2A).
To examine how the level of antigen affected T cell specific T cells that might magnify T cell responses by an
artificial bystander effect (Ehl et al., 1997). We thereforeresponses to other antigens, we created an inducible
gp33 vector (igp33-LEGFP) to generate cell populations examined if solid tumors also induced natural T cell
responses. We challenged C57BL/6 mice with SIY-1,that expressed higher or lower levels of the KAVYNFATM
epitope, which is derived from the LCMV protein gp33 SIY-2Hi, or SIY-2Lo tumor fragments. SIY-1 or SIY-2Hi
tumors induced circulating anti-SIY CD8 T cells that(Figure 2C). In the uninduced state, gp33-1Lo cells (MFI
5.31) expressed the gp33 antigen approximately 2.25- produced IFN upon restimulation with the SIY peptide
(Figure 3A). T cells specifically responded to the SIYfold above the Neo clone (MFI 2.36). In the induced state,
gp33-1Hi cells (MFI 123.49) expressed approximately peptide because restimulation with a mutant p68 heli-
case peptide, which is the immunodominant antigen23-fold higher levels of gp33 than gp33-1Lo cells. We
then challenged 2C mice with gp33-1Hi and gp33-1Lo of a UV-induced regressor tumor, failed to induce any
response. In addition, IFN-expressing cells were notcells. After 16 days of tumor growth, we transferred
CFSE-labeled P14 T cells into the tumor-bearing mice. detected with an isotype control antibody (data not
shown). Furthermore, SIY-1 or SIY-2Hi tumors primedAt this time, the gp33-1Lo tumors had reached a size
of 810 mm3 and the gp33-1Hi tumor had reached a size CTLs specific for the SIY antigen (Figure 3B). In contrast,
mice challenged with SIY-2Lo tumor fragments did notof 819 mm3. After 3 days, analysis of the DLN revealed
that P14 T cells also proliferated significantly more in generate effective, cytolytic T cell responses against the
SIY antigen. Mice challenged with cell suspensions ofthe DLN of mice bearing gp33-1Hi tumors compared to
mice bearing gp33-1Lo tumors. Thus, growing tumors SIY-1, SIY-2Hi, or SIY-2Lo cells generated anti-SIY CD8
T cells that produced IFN and were cytolytic (data notthat expressed lower levels of antigen induced substan-
tially less T cell proliferation than growing tumors ex- shown). Thus, only solid tumors expressing relatively
high levels of antigen primed natural CTL responses.pressing higher levels of antigen.
Induced Antigens Overcome Ignorance to Tumors
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Figure 3. Solid Tumors Expressing Higher Levels of the SIY Antigen Induce Circulating anti-SIY CD8 T Cells that Produce IFN and Are
Cytolytic after Restimulation in Culture
(A, upper panels) C57BL/6 mice were challenged with the indicated tumor fragments; 8 days later, anti-SIY-specific CD8 T cells were detected
in PBL of mice challenged with SIY-1 or SIY-2Hi tumors using SIY:Ig dimers.
(A, lower panels) Nine days after tumor challenge, splenocytes were restimulated with 1 g/ml of the SIYRYYGL peptide. Six hours later, IFN
was detected in CD8 T cells of mice challenged with SIY-1 or SIY-2Hi tumors. Numbers in the upper right corners indicate the percentage
of total cells in the respective quadrant.
(B) Splenocytes were restimulated with 1 M of the SIYRYYGL peptide for 5 days. SIY-1 and SIY-2Hi tumor challenges primed CTLs as
detected in a 4.5 hr 51Cr release assay.
2C T Cells in the DLN Respond Effectively to Solid the Ld antigen. In addition to recognizing the SIY antigen,
2C T cells also recognized Ld, which is an allogeneicTumors Expressing Antigens that
Can Be Crosspresented MHC class I molecule that presents peptides derived
from the house-keeping gene 	-ketoglutarate dehydro-Antigenic cancer cells can localize to the lymph nodes
and directly prime CTL responses (Ochsenbein et al., genase (Udaka et al., 1992). 2C T cells only recognized
MC57 cells directly presenting Ld because 2C T cell1999, 2001). Since the SIY antigen is both directly and
crosspresented, we could not specifically determine if responses required Ld in its native form, which is lost
when the antigen is processed and crosspresented bytumors expressing SIY directly primed 2C T cells. There-
fore, we examined if solid tumors could directly prime APCs. The MC57-Ld clone (Ld) (MFI  1176) stained for
Ld 258-fold more than the background control (MFI 2C T cells in the DLN by transfecting MC57 cells with
Immunity
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Figure 4. Only Solid Tumors that Express a
Crosspresented Antigen Induce 2C T Cell
Proliferation and Expression of CD44 and
IFN in the DLN
(A) MC57 cells were transfected with pcDNA-
Ld to generate MC57-Ld (Ld) that expressed
Ld at levels similar to P815. For EGFP fluores-
cence: shaded curve, indicated transfectant;
unshaded curve, MC57-Neo. For Ld staining:
shaded curve, anti-Ld staining; unshaded
curve, secondary antibody only.
(B) Cytolytic 2C T cells fail to lyse MC57-EGFP
but lyse MC57-Ld similar to P815 and SIY-1 in
a 4.5 hr 51Cr release assay. 2C T cells similarly
lysed cancer cells expressing SIY or Ld.
(C)107 CFSE-labeled 2C T cells were trans-
ferred into C57BL/6 mice, and the next day
mice were challenged with the SIY-1 or Ld
tumor fragments. In addition, mice were chal-
lenged with EGFP, Ld, or P815 cell suspen-
sions. Three days later, only solid tumors ex-
pressing SIY induced 2C T cell proliferation
in the DLN.
(D) Solid tumors expressing SIY induced CD44
and IFN expression in proliferating 2C T cells.
4.55) and at a similar level as the mastocytoma P815 in 2C mice (data not shown), P815 cells are rejected
(Manning et al., 1997). Unlike MC57 cells, P815 cells(Figure 4A). We also controlled for immune responses
against EGFP by generating MC57 cells expressing might be rejected despite failing to induce T cell prolifer-
ation in the DLN because they are of hematopoieticEGFP. Cytolytic 2C T cells similarly lysed P815, Ld, and
SIY-1 cancer cells but failed to lyse EGFP-expressing origin. In addition, the cells are allogeneic transplants
which may induce innate (i.e., NK cells) responses ascancer cells (Figure 4B).
We transferred CFSE-labeled 2C T cells into C57BL/6 well as induce other factors as previously described by
Kedl and Mescher (1997). MC57 tumors expressing Ldmice and challenged these mice with Ld or SIY-1 tumor
fragments. Three days after tumor challenge, 65.8% of grew in 2C mice (data not shown), consistent with previ-
ous observations that immune responses in the DLN2C T cells proliferated in response to SIY-1 tumors (Fig-
ure 4C). In contrast, 98.6% of 2C cells did not divide in were important for the rejection of solid tumors (Och-
senbein et al., 1999).response to Ld-expressing tumor fragments. Since the
2C TCR binds to Ld with a 30-fold greater affinity than In response to SIY-1 tumor fragments, 2C T cells pref-
erentially proliferated in DLN compared to the NDLNto the SIY antigen, 2C T cell responses to the SIY antigen
were not likely due to a higher affinity for this antigen (67.8% divided in DLN versus 1.1% divided in NDLN;
Figure 4C). At later times, we did detect CFSElo 2C T(Garcia et al., 1997). 2C T cells did not proliferate in
response to EGFP, indicating that the response was cells in the NDLN, suggesting that activated T cells had
begun to circulate (data not shown). 2C T cells, whichspecific for SIY. Suspensions of P815 cells or Ld cells
did not induce 2C T cell proliferation in the DLN (Kedl had divided, increased expression of the activation
marker CD44 and produced the effector molecule IFNand Mescher, 1997). It is possible that the level of endog-
enous 	-ketoglutarate dehydrogenase is too low for us (Figures 6B and 6C). After five divisions, more T cells
expressed IFN than the undivided population (49.2%to observe direct priming in the DLN. In any case, the
level of antigen expressed by P815 is sufficient to di- IFN T cells after five generations versus 8.5% IFN
in undivided population, Figure 6C). Thus, T cells failedrectly prime 2C T cells at the tumor site (Kedl and
Mescher, 1997). Whereas suspensions of Ld cells grew to respond to solid tumors expressing an antigen that
Induced Antigens Overcome Ignorance to Tumors
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Figure 5. MC57-SIY-1 Cells of Solid Tumors
Are Not Detected in the DLN
(A) SIY-1 cancer cells were mixed with 107
LN cells at the indicated ratios, and genomic
DNA was isolated. PCR for the EGFP gene
detected SIY-1 cells with a sensitivity of one
cancer cell per 106 LN cells.
(B) Mice were injected with SIY-1 tumor frag-
ments or suspensions of 5 106 cancer cells,
and the DLN were harvested on day 1 (d1) or
day 2 (d2).
(C) Mice were injected with SIY-1 tumor frag-
ments or suspensions of 5  106 cancer cells
and the DLN were harvested on day 4 (d4) or
day 8 (d8). PCR failed to detect cancer cells
in the DLN of mice challenged with solid tu-
mors. As a loading control, the PCR reactions
were diluted 1:100 and subjected to PCR us-
ing p68-specific primers. Ladder, 1 kilobase
pair ladder; primers, no DNA; vector, pcDNA-
SIY DNA; 1 SIY cell, 1 MC57-SIY-1 cell per
106 LN cells; N, DNA from DLN of a naive
mouse; SIY-1 DNA, genomic DNA from SIY-1
cells.
is only directly presented but effectively responded to results indicate that 2C T cell proliferation could occur
in the absence of detectable cancer cells in the DLN,tumors expressing an antigen that can be cross-
presented. presumably because other nonmalignant cells pre-
sented the SIY antigen. Therefore, we examined if cells
in the tumor stroma presented the SIY antigen to 2C TCancer Cells in Solid Tumors Fail to Localize
cells.to the Draining Lymph Node
As a solid tumor, MC57 cancer cells fail to be detected
in the DLN, suggesting that these cells did not spontane- Syngeneic Bone Marrow-Derived Cells in the Tumor
Stroma Are Required for 2C T Cell Proliferationously disseminate to the lymphoid organs and directly
prime immune responses (Ochsenbein et al., 1999, in the DLN
We reasoned that the H-2k haplotype would not present2001). To further exclude the possibility that SIY-1 tu-
mors directly primed immune responses, we analyzed the SIY antigen because 2C T cells do not survive in
mice expressing these MHC restriction elements (Chothe DLN for SIY-1 cancer cells by PCR. We used a PCR
assay capable of detecting one cancer cell in 106 LN et al., 2000). Therefore, we grew SIY-1 or SIY-2Hi cells
in C3H nude mice to generate solid tumors with H-2kcells (Figure 5A). We challenged mice with SIY-1 tumor
fragments or cell suspensions. Within 2 to 4 days, we restricted stroma. 2C T cells did not proliferate in re-
sponse to tumor transplants containing C3H stromadetected the genomic DNA in the DLN of mice chal-
lenged with a cancer cell suspension (Figures 5B and (Figures 6A and 6B). In contrast, T cells proliferated in
response to tumors containing syngeneic H-2b stroma,5C). However, we did not detect genomic DNA in the
DLN of mice challenged with solid tumors. Thus, these suggesting that T cell responses required stromal cells
Immunity
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Figure 6. 2C T Cell Proliferation in Response
to MC57 Tumors Expressing SIY Requires
Syngeneic Stroma
(A) SIY-2Hi tumor fragments were grown in
C57BL/6-RAG1/ mice (C57BL/6) or C3H
nude mice (C3H/HeN). CFSE-labeled 2C T
cells were transferred into C57BL/6 mice, and
the next day the mice were challenged with
SIY-2Hi tumor fragments containing C57BL/6
stroma or C3H stroma. Four days later, 2C
T cells proliferated primarily in response to
tumors containing C57BL/6 stroma that can
present the SIY antigen.
(B) SIY-1 tumors were grown in C57BL/6-
RAG1/ mice (C57BL/6), C3H nude mice
(C3H/HeN), or C3H nude mice that received
C57BL/6-RAG1/ bone marrow (B6→C3H).
CFSE-labeled 2C T cells were transferred into
C57BL/6 mice, and the next day the mice
were challenged with SIY-1 tumor fragments
containing the indicated stroma. Three days
later, 2C T cells proliferated primarily in re-
sponse to tumors containing C57BL/6 stroma
that can present the SIY antigen.
that crosspresented the SIY antigen. Since bone mar- transfected clones. Furthermore, T cells responded only
to tumors containing syngeneic stroma, suggesting thatrow-derived cells can crosspresent tumor antigens
(Huang et al., 1994; Nguyen et al., 2002), we determined stroma contained APCs which crosspresented tumor anti-
gens in the DLN. We suggest that crosspresentationif H-2b-expressing stromal cells presented antigens to
2C T cells in the draining lymph nodes (Figure 6B). We by nonmalignant cells in the tumor stroma determines
whether antigens are expressed at levels sufficient to in-transferred C57BL/6-RAG1/ bone marrow into C3H
nude mice and 3 weeks later injected the H-2b bone- duce effective immune responses against solid tumors.
To explain why the level of antigen expression deter-marrow chimeric C3H mice with SIY-1 cells. 2C T cells
did proliferate in response to tumor fragments con- mines whether solid tumors are rejected, we used 2C T
cells to track a single CD8 T cell response to tumortaining H-2b bone marrow-derived cells in the tumor
stroma capable of presenting the SIY antigen. Antigen antigens in the DLN. The SIY antigen models tumor-
specific antigens that are products of mutant genespresentation by bone marrow-derived stromal cells re-
stored the ability of 2C T cells to respond to solid tumors, expressed by many human and experimental cancers
(Coulie et al., 1995; Dubey et al., 1997; Monach et al.,suggesting that bone marrow-derived cells in the stroma
pick up antigen at the tumor site and traffic to the DLN 1995; Wolfel et al., 1995). Although direct priming can
occur at the tumor site (Kedl and Mescher, 1997),where they crosspresent antigens to induce a T cell
response. lymphoid organs may be important for the rejection of
solid tumors (Ochsenbein et al., 1999). In any case, 2C
T cell responses in the DLN correlated with cytotoxic TDiscussion
lymphocyte responses and tumor rejection.
Our study shows that tumor immunity may be affectedIn this study, we showed that cancer cells expressing
antigens at relatively low levels failed to induce CD8 T by both the level of antigen expression and by the stroma
encasing the cancer cells expressing these antigens.cell responses and be rejected when these cancer cells
were embedded in the stroma of a solid tumor. In con- Previous studies of peripheral tissues have demon-
strated that CD8 T cells remained ignorant of antigenstrast, solid tumors expressing higher levels of antigen
induced effective cytolytic T cell responses and were expressed at lower levels (Kurts et al., 1999). In contrast,
antigens expressed at higher levels are crosspresentedrejected. We draw our conclusions that the antigen level
was the critical variable because we compared immune to induce T cell tolerance. Neoplastic transformation
and tumor growth also enhanced T cell activation, dueresponses against tumors derived from a single clone.
By using a single clone, our conclusions are not likely in part to more cancer cells expressing antigen (Cordaro
et al., 2000; Nguyen et al., 2002). The level of expressionto be influenced by changes that are unrelated to the
level of antigen expression and can occur in independently likely limits which antigens can sensitize cells to lysis
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by CTLs (Goodnow, 1999). Our findings suggest that immune system to respond against self-proteins, such
as in autoimmunity, or against alloantigens, such as ineven fewer antigens may be crosspresented than serve
as a target for CTLs and, therefore, further limit which transplantation immunology.
antigens can induce an immune response.
Experimental ProceduresThe level of antigen expression necessary for solid
tumors to induce an immune response was likely deter-
Mice, Cell Lines, and Reagents
mined by the efficiency at which the antigen is cross- Female C57BL/6, BALB/c, and C3H/HeN nude mice were purchased
presented (Carbone et al., 1998). T cell responses in the from the National Cancer Institute, Frederick Cancer Research Facil-
DLN required bone marrow-derived cells, suggesting ity (Frederick, MD). B6.129S7-Rag1tm1Mom (Rag1/) and C57BL/6-
TgN(ACTbEGFP)Osb (EGFP) mice were purchased from The Jack-that dendritic cells in the solid tumor trafficked to the
son Laboratory (Bar Harbor, ME). Matthew Mescher (University ofDLN to prime a T cell response. Antigens expressed at
Minnesota, MN) provided the OT-1 mice; Philip Ashton-Rickardthigher levels most likely overcome the loss of these
(The University of Chicago, Chicago) provided the P14 mice. 2C 
antigens during their transfer and crosspresentation by Rag2/ mice were bred to C57BL/6 mice to generate 2C Rag2/
APCs in the tumor stroma. Antigens expressed at lower mice. For B6→C3H bone marrow chimeras, C3H nude mice were
irradiated with 6 Gy and 3 hr later received 107 RAG1 bone marrowlevels may fail to be presented by APCs and, therefore,
cells. The C3H recipients were injected with SIY-1 or SIY-2Hi at leastdo not prime immune responses against solid tumors.
3 weeks after bone marrow transfers. Pamela Ohashi (University ofPrevious models may not have detected an immune
Toronto, Canada), with permission of Hans Hengartner (Universityresponse to solid tumors because the model antigens
Hospital, Zurich, Switzerland), provided the MC57G fibrosarcoma
used in these systems may have been expressed at cell line. The mastocytoma cell line P815 was obtained from Theirry
lower levels (Ochsenbein et al., 1999, 2001). We found Boon (University de Louvain, Brussels, Belgium). These cell lines
were maintained in Dulbecco’s Modification of Eagle’s Medium (In-that in the absence of tumor stroma, suspensions of
vitrogen, Carlsbad, CA) supplemented with heat-inactivated 5%–cancer cells expressing lower levels of antigen primed
10% fetal calf serum (FCS). The anti-Kb antibody (clone Y3) and thean immune response. These results suggest that SIY-
anti-Ld antibody (clone 30-5-7) were obtained from David SachsLo cells either reached the lymphoid organs to directly
(Massachusetts General Hospital, Boston). The clonotypic anti-2C
prime T cells (Ochsenbein et al., 1999, 2001) or were TCR antibody, 1B2, was obtained from Herman Eisen (MIT, Cam-
processed more efficiently by APCs to crossprime T bridge, MA). The PE anti-IFN antibody (clone XMG 1.2), isotype
control PE rat IgG1 antibody (clone A110-1), FITC anti-CD8	 antibodycells (Singh et al., 1992). Thus, the rejection of solid
(clone 53-6.7), CyC anti-CD44 antibody (clone RA3-6B2), PE anti-tumors but not suspended cancer cells may require anti-
mouse IgG1 (clone A85-1), APC anti-mouse IgG1 (clone X56), andgens expressed at levels sufficient to be picked up and
the Kb:IgG Dimer X were purchased from Pharmingen (San Diego,crosspresented by bone marrow-derived APCs in the
CA). The PE anti-mouse IgG was purchased from Southern Biotech-
tumor stroma. nology Associates (Birmingham, AL). The SIY peptide SIYRYYGL
While the immune system may fail to respond effec- and the mutant p68 peptide SNFVFAGI were synthesized by FMOC
chemistry. Brefeldin A (BFA), ionomycin, and phorbol 12-myristatetively to antigens expressed at lower levels by solid
acetate (PMA) were purchased from Sigma Chemical Co. (St. Louis,tumors, the level of antigen expression may not be the
MO). Carboxyfluorescein diacetate succinimidyl ester (CFSE) wasonly factor that determines whether a growing tumor is
purchased from Molecular Probes (Eugene, OR). All oligonucleo-rejected. In fact, established tumors can induce numer- tides were synthesized by IDT (Coralville, IA).
ous mechanisms that suppress an effective immune re-
sponse. These mechanisms, which may be strongest at 51Cr Release Assay
To generate cytolytic 2C T cells, 106 NH4Cl-treated splenocytes fromthe tumor site, include regulatory T cells, suppressive
a 2C Rag mouse were stimulated with 6  106 NH4Cl-treated, irradi-cytokines, and regulation of the signal transduction
ated (2000 rad) splenocytes from a BALB/c mouse. For detectingpathway of lymphocytes (Matsuda et al., 1995; Mizo-
CTL priming, 8  106 splenocytes from primed mice were exposedguchi et al., 1992; Sutmuller et al., 2001; Wick et al.,
to 1 M of the SIYRYYGL peptide in a 15 ml rounded bottom, screw
1997). While these mechanisms may prevent immune cap tube containing 3 ml cRPMI (RPMI 1640 [Invitrogen] with 25 mM
responses against a growing tumor, the level of antigen HEPES supplemented with 10% Fetal Calf Serum, 2 mM L-gluta-
expression may ultimately determine whether an effec- mine, 1 mM sodium pyruvate, 0.1 mM nonessential amino acids,
50 M 
-mercaptoethanol, 50 U/ml penicillin, and 50 g/ml strepto-tive immune response can be initiated.
mycin). After 5 days, Cr release assays were performed as previouslyIt is likely that human tumors express many antigens
described (Dubey et al., 1997).at levels that are not sufficient for crosspresentation.
Since such antigens would fail to induce an immune Generation of SIY and Ld Expression Vectors and Clones
response, growing tumors may retain antigens ex- To generate pcDNA3.1-Ld, the LK444 plasmid containing Ld cDNA
pressed at lower levels that still serve as a target for (Andrea Sant, University of Chicago) was digested with EcoRI and
ligated to an EcoRI-digested, calf-intestinal phosphatase-treatedrecognition by CTLs. Thus, apparently nonimmunogenic
pcDNA 3.1 (Invitrogen). To generate iSIY-LEGFP, an SIY minigenetumors may contain antigenic cancer cells that are po-
was made from two dsDNA oligonucleotides (SIY-5 and SIY-3) thattential targets for T cells primed by effective vaccines
were annealed, phosphorylated, and ligated together. SIY-5 was(Dalyot-Herman et al., 2000; Schuler and Steinman,
made by annealing 5-TCGACGCCACCATGGTGTCTATTTACAGGT
1997). Our model for tumor recognition may also explain ACTACGGCCTGGCTGCTTACTCTATTTACA-3 with 5-TACCTGT
why certain antigens expressed by nonmalignant tis- AAATAGAGTAAGCAGCCAGGCCGTAGTACCTGTAAATAGACAC
sues fail to induce an effective immune response, re- CATGGTGGCG- 3 . S IY -3 made by annealing 5  -GGTACTA
CGGCCTGGCTGCTTACTCTATTTACAGGTACTACGGCCTGGCTGsulting in a state of immunological ignorance. Our results
CTTACGGG-3 with 5-GATCCCCGTAAGCAGCCAGGCCGTAGsuggest that ignorance is determined both by the level
TACCTGTAAATAGAGTAAGCAGCCAGGCCGTAG-3. Bold text indi-of antigen expressed by the parenchymal cells and by
cates SalI and BamHI overhangs for SIY-5 and SIY-3, respectively;
the ability of the surrounding stroma to crosspresent the underlined base pairs indicate the overhang of SIY-5 that is
these antigens. Therefore, the context in which an anti- complimentary with the overhand of SIY-3. The SIY minigene was
ligated to a SalI-BamHI fragment of pLEGFP (Clontech, Palo Alto,genic cell resides may affect the ability or failure of the
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CA), generating SIY-LEGFP. A multiple cloning site flanked by loxP sions were injected on the posterior side of the mouse 1–3 cm directly
above the base of the tail. For assays of tumor growth, tumor fragmentssites was ligated to a BglII-SalI fragment of SIY-LEGFP to generate
or cancer cell suspensions were injected in the flank.an MCS-SIY-LEGFP vector. A PmeI fragment containing HLA-A2.1
and the puromycin resistance gene was ligated to a PmeI-digested
Western Analysisfragment of MCS-SIY-LEGFP to generate an inducible SIY (iSIY-
A tumor fragment inoculum or 5  106 of the corresponding cancerLEGFP) vector. HLA-A2.1 expression enabled us to select for clones
cell suspension was pelleted by centrifugation. The pellet was lysedthat would express SIY at high levels upon recombination of the
with a modified radio-immunoprecipitation assay buffer (50 mM Tris-loxP sites. To generate igp33-LEGFP, a gp33 minigene was made
HCl [pH 7.4], 150 mM NaCl, 1M EDTA, 1% NP40, 1 g/ml aprotinin,from two dsDNA oligonucleotides similar to the SIY minigene except
1 g/ml leupeptin, and 10 M PMSF) for 30 min on ice; during thisthat the nucleic acid sequence coding for the SIYRYYGL epitope
time, the pellet was ground briefly using a disposable pestle. Thewas replaced by AAGGCTGTGTACAATTTCGCTACCATG coding for
cell debris was pelleted by centrifugation, and the lysate was storedthe KAVYNFATM epitope.
at –20C. Samples were subjected to SDS-PAGE using a 4% stack-To generate pcDNA-SIY, SIY-LEGFP was digested with EcoRI-
ing gel and a 10% resolving gel. In a single gel, we compared aBamHI, and the fragment containing the SIY peptide was ligated
dilution of an EGFP standard to a dilution of a tumor fragmentto an EcoRI-BamHI fragment of pcDNA3.1. The EGFP gene was
or cancer cell lysate. As a standard, recombinant EGFP proteingenerated by PCR using the primers 5-GGGGATCCAGGCGGCGG
(Clontech) was loaded onto a single gel at 100 ng, 30 ng, 10 ng, orCATGGTGAGCAAG-3 and 5-CCAAGCTTCATTGATGAGTTTGGA
3 ng per lane. In the same gel, tumor fragment lysates were loadedCAAACC-3. This EGFP PCR product was digested with BamHI and
at 1:10, 1:30, 1:100, 1:300 dilutions per lane. Similarly, lysates of cellHindIII and ligated to a BamHI-HindIII fragment of pcDNA3.1-SIY to
suspension were loaded at 3  105, 1  105, 3  104, 1  104, andgenerate the vector pcDNA3.1-SIY-EGFP.
3103 cell equivalents per lane. The protein gel was then transferredTo generate MC57-Ld and MC57-SIY-1, MC57G cells were trans-
to nitrocellulose, blocked, and probed using a 1:200 dilution of afected with pcDNA3.1-Ld or pcDNA3.1-SIY-EGFP using Superfect
primary Living Color A.v. peptide antibody (Clontech) and subse-
(Qaigen, Valencia, CA) and cloned by limiting dilution. MC57G was
quently a 1:1000 dilution of a secondary HRP conjugated goat anti-
transfected with MerCreMer provided by Michael Reth (Max Plank
rabbit IgG antibody (Pierce, Rockford, IL). The membrane was devel-
Institute for Immunobiology, Freiburg, Germany) to generate MC57-
oped using ECL (Amersham, Arlington Heights, IL). Each blot was
Neo (Neo). Neo was transfected with iSIY-LEGFP or igp33-LEGFP, analyzed using Gel expert software (Nucleotech). For each blot,
selected with 5 g/ml puromycin and cloned by limiting dilution to three to four concentrations of the EGFP standard were subjected
generate SIY-2Lo or gp33-1Lo, respectively. SIY-2Lo or gp33-1Lo to linear regression analysis giving an average R value of 0.9704 
cells were treated with 200 nM 4-hydroxytamoxifen for 4 days to 0.0076 (n  4). The corresponding EGFP concentration of a given
generate SIY-2Hi or gp33-1Hi cells, respectively. fragment or cancer cell dilution was then calculated and compared.
Analysis of Cells by FACS PCR Analysis of Tumor Draining LN
For analysis of Kb or Ld expression, cancer cells were incubated Genomic DNA from 107 LN cells was isolated using QIAamp DNA
with the anti-Kb or anti-Ld antibodies, washed, and incubated with mini kit. 106 cell equivalents (20 L) were subjected to PCR analysis
the PE anti-mouse IgG antibody. For analysis of IFN- production, using the 20 pmol of the EGFP-specific primers: 5-AGCTGACCCT
cells were incubated with no peptide, 50 ng/ml PMA  5 g/ml GAAGTTCATCTG-3 and 5-TATAGACGTTGTGGCTGTTGTAGTT-
ionomycin, 1 g/ml of SIY, or 1 g/ml mutant p68 in the presence 3. The template was denatured at 94C for 45 s; the primers were
of 10 g/ml BFA in cRPMI at 37C. After 5–6 hr, the cells were fixed annealed at 65C for 1 min and extended at 72C for 1 min and
with 4% paraformaldehyde and permeablilzed with 0.5% saponin repeated for 33 cycles. As a loading control, the resulting PCR
in PBS with 1% BSA and 0.1% azide. The mutant p68 peptide products were diluted 1:100 and 1 l was subjected to PCR using
(SNFVFAGI) is the immunodominant epitope of the UV-induced fi- the housekeeping gene p68 RNA helicase-specific primers 5-
brosarcoma 8101RE (Dubey et al., 1997). The cells were stained AGAATACCCTGTTGGCATGG-3 and 5-GGAGCTTTGGAAGTAAT
with PE anti-IFN or the isotype control. For analysis of anti-SIY T TTTGTTTC-3.
cells, Kb-IgG Dimer X were loaded with a 40 molar excess of the
SIY peptide or the mutant p68 peptide and peripheral blood lympho- Acknowledgments
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